ZENORA™️ 30 MG

Balance. Adapt. Explore.

Experience advanced neuroscience research with ZENORA™️ 30 MG, featuring PE-22-28, an experimental synthetic peptide investigated primarily for its potential effects on neuroplasticity, stress-related behavior, mood-related pathways, and neuronal signaling.

Designed for advanced neurobiological research, ZENORA™️ focuses on mechanisms associated with brain adaptability, synaptic function, and emotional-behavioral regulation.

---

The Science of Neuroplasticity

PE-22-28 — 30 MG

PE-22-28 is a short synthetic peptide derived from research involving spadin-related peptides and the TREK-1 potassium channel, a channel involved in neuronal excitability and neurobiological pathways relevant to mood and stress.

Preclinical research has explored PE-22-28 in areas involving:

• Neuroplasticity
• Synaptic signaling
• Stress-response pathways
• Mood-related behavioral models
• Neuronal communication
• Cognitive and emotional processing

The research focus: Neuroplasticity + neural adaptation + mood pathways + stress-response research.

---

Key Research Areas

• Investigated for neuroplasticity-related mechanisms
• Supports research into neuronal adaptability
• Studied in mood-related experimental models
• Investigated for TREK-1–related signaling
• Supports synaptic-function research
• Studied in stress-response pathways
• Explored in cognitive and behavioral neuroscience
• Provides a platform for advanced neurological research

---

Crafted for Advanced Research

Designed for research focused on:

• Neuroplasticity
• Mood-related pathways
• Stress adaptation
• Synaptic function
• Neuronal signaling
• Emotional-behavioral mechanisms
• Cognitive neuroscience
• Brain adaptability

---

Product Details

PE-22-28

Advanced Neuroplasticity Research Peptide
Total: 30 MG

• PE-22-28 (30 MG): Neuroplasticity • Adaptation • Mood Pathway Research

---

Scientific Perspective

PE-22-28 has attracted scientific interest through research involving TREK-1, a two-pore-domain potassium channel associated with neuronal excitability and several neurobiological processes.

Experimental studies involving spadin-derived peptides have reported antidepressant-like behavioral effects and neuroplasticity-related changes in preclinical models, contributing to interest in this peptide family.

However, PE-22-28 remains highly experimental. Evidence is predominantly preclinical, and there is currently insufficient high-quality human clinical evidence to establish its effectiveness, optimal dose, long-term safety, or suitability for treating depression, anxiety, or other neurological or psychiatric conditions.

---

Research & Handling

ZENORA™️ should be approached as an experimental research formulation.

Concentration, preparation, administration route, and experimental parameters should follow an appropriately designed research protocol.

It should not be presented as an established treatment for depression, anxiety, cognitive impairment, or other psychiatric or neurological conditions.

---

Why Choose Stayfit Pharma

When quality matters, precision defines the difference.

• 99%+ purity research peptides
• Manufactured under strict quality standards
• Advanced formulations for neuroscience research
• Premium-grade ingredients and quality control

---

ZENORA™️ 30 MG
PE-22-28 30 MG
Advanced Neuroplasticity Research Peptide
Balance • Adapt • Explore